GH Research PLC (NASDAQ:GHRS) Receives $40.38 Consensus PT from Brokerages

Shares of GH Research PLC (NASDAQ:GHRS) have received a consensus rating of “Moderate Buy” from the eleven research firms that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating and nine have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $40.3750.

GHRS has been the topic of a number of analyst reports. HC Wainwright decreased their price objective on GH Research from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a research note on Friday, July 17th. Zacks Research lowered GH Research from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 15th. Citigroup restated an “outperform” rating on shares of GH Research in a research note on Friday, May 15th. Finally, Citizens Jmp decreased their target price on shares of GH Research from $42.00 to $39.00 and set a “market outperform” rating on the stock in a research report on Friday, May 15th.

Hedge Funds Weigh In On GH Research

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Barclays PLC boosted its stake in shares of GH Research by 63.4% during the 4th quarter. Barclays PLC now owns 2,118 shares of the company’s stock valued at $27,000 after buying an additional 822 shares during the last quarter. North Star Investment Management Corp. bought a new position in GH Research in the first quarter worth about $31,000. Royal Bank of Canada boosted its stake in GH Research by 43.1% in the first quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock valued at $36,000 after acquiring an additional 780 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of GH Research during the fourth quarter valued at approximately $38,000. Finally, Osaic Holdings Inc. raised its position in shares of GH Research by 63.6% during the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after purchasing an additional 2,400 shares during the period. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Stock Down 1.3%

GHRS stock opened at $27.28 on Monday. The firm has a market cap of $1.87 billion, a P/E ratio of -29.65 and a beta of 1.28. GH Research has a 52-week low of $11.32 and a 52-week high of $31.00. The company’s 50-day simple moving average is $24.43 and its 200-day simple moving average is $19.27.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.04). On average, analysts anticipate that GH Research will post -1.46 earnings per share for the current fiscal year.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.